☰

Hannah M. King - Publications

Affiliations: 
2017-2021 Eppley Institute for Cancer Research University of Nebraska Medical Center, Omaha, NE, United States 
Tree Info Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Napoleon JV, Sagar S, Kubica SP, Boghean L, Kour S, King HM, Sonawane YA, Crawford AJ, Gautam N, Kizhake S, Bialk PA, Kmiec E, Mallareddy JR, Patil PP, Rana S, et al. Small-molecule IKKβ activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth. Proceedings of the National Academy of Sciences of the United States of America. 119: e2115071119. PMID 35476515 DOI: 10.1073/pnas.2115071119  0.776
2022 Rana S, Kour S, Kizhake S, King HM, Mallareddy JR, Case AJ, Huxford T, Natarajan A. Dimers of isatin derived α-methylene-γ-butyrolactone as potent anti-cancer agents. Bioorganic & Medicinal Chemistry Letters. 65: 128713. PMID 35367592 DOI: 10.1016/j.bmcl.2022.128713  0.808
2021 King HM, Rana S, Kubica SP, Mallareddy JR, Kizhake S, Ezell EL, Zahid M, Naldrett MJ, Alvarez S, Law HCH, Woods NT, Natarajan A. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Bioorganic & Medicinal Chemistry Letters. 128061. PMID 33895280 DOI: 10.1016/j.bmcl.2021.128061  0.569
2019 Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429. PMID 31467029 DOI: 10.1124/Mol.119.116855  0.759
2019 Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429. PMID 31467029 DOI: 10.1124/Mol.119.116855  0.759
2019 Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, Natarajan A. Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic & Medicinal Chemistry Letters. PMID 30935795 DOI: 10.1016/J.Bmcl.2019.03.035  0.796
2019 Rana S, Bendjennat M, Kour S, King HM, Kizhake S, Zahid M, Natarajan A. Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic & Medicinal Chemistry Letters. PMID 30935795 DOI: 10.1016/J.Bmcl.2019.03.035  0.796
2018 Contreras JI, Robb CM, King HM, Baxter J, Crawford AJ, Kour S, Kizhake S, Sonawane YA, Rana S, Hollingsworth MA, Luo X, Natarajan A. Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. Acs Chemical Biology. PMID 29608269 DOI: 10.1021/Acschembio.8B00077  0.756
2018 Contreras JI, Robb CM, King HM, Baxter J, Crawford AJ, Kour S, Kizhake S, Sonawane YA, Rana S, Hollingsworth MA, Luo X, Natarajan A. Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. Acs Chemical Biology. PMID 29608269 DOI: 10.1021/Acschembio.8B00077  0.756
Show low-probability matches.